Plain-English translation of NCT06462547 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
The ADAPT Study is testing a new medication called designed to treat two rare genetic conditions: ENPP1 deficiency and ABCC6 deficiency. These conditions cause problems with how calcium builds up in the body and can lead to joint stiffness, bone problems, and calcium deposits in blood vessels. This long-term study tracks whether the medication is safe to use over time in patients who have already been treated with it in earlier research.
Very few treatment options exist for these rare genetic disorders, and doctors need to understand whether this new medication can be given safely over extended periods. This study helps determine if the treatment can be used long-term without serious side effects.
You will receive an injection of the medication under your skin once each week. The study continues until the medication becomes available through regular prescription channels in your country or until the company stops development. You will have regular visits with the research team to check your health and safety, and you'll complete a final follow-up visit about 30 days after your last injection to make sure you're doing well.
AI-generated summary from trial data · Aug 28, 2026 · Not medical advice
United States
France
Germany
United Kingdom